Delivery Order SPE2DB22D2206-SPE2DB24FFV27
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 mg/10 mL vials. The delivery order, valued at $23,118.08, has an ultimate completion date of April 22, 2024. This award is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a period of performance through...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division to provide Ocrevus 300 mg/10 ml vials. The fixed-price contract, valued at $69,354.24, has a completion date of June 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for...
- The U.S. Defense Logistics Agency Troop Support Medical has awarded a $115,590.40 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4564133145 OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. The contract has a ceiling value of $46,236.16 and runs through April 22, 2024. This delivery order falls under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with a potential value of up to $999,999,999.00 and a...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to the Corporate Office division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide OCREVUS 300 MG/10 ML VIAL 10ML. The $23,118.08 contract has a June 3, 2024 ultimate completion date. This award is made under Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product OCREVUS 300 MG/10 ML VIAL 10ML. The order has a potential value of $23,118.08 and a completion date of March 12, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is issued under a larger indefinite delivery contract (IDC) the company...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. The $23,118.08 firm fixed-price contract does not have a set-aside designation and has a period of performance through July 16, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to...
- The Defense Logistics Agency awarded a delivery order valued at $25,637.70 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on January 27, 2026, with an ultimate completion date of February 18, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal government healthcare...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract worth $23,118.08 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML. This contract has a completion date of March 27, 2024 and was awarded on March 6, 2024. No set-aside designation was used. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical with a potential...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract, valued at up to $115,590.40, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. This is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FFV27Delivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $115,590.40 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide OCREVUS 300 mg/10 ml vials with a completion date of March 20, 2024. This contract is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. No set-aside designation was used for this specific delivery order.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $115.6k | 2/28/24 |